David J. Brayden

TL;DR: This review will discuss recent achievements in PEGylation processes with an emphasis on novel PEG-drugs constructs, the unrealized potential of P EGylation for non-injected routes of delivery, and also on PEGYLated versions of polymeric nanoparticles, including dendrimers and liposomes.

TL;DR: A new, simplified in vitro model of the human M-cell is established to enable controlled studies of M- cell development and function in vitro.

TL;DR: The affinity of PLA particles for intestinal epithelia and GALT needs to be greatly enhanced in order to achieve improved oral bioavailability of macromolecules.

TL;DR: This article assesses the intestinal permeation enhancement action of over 250 PEs that have been tested in intestinal delivery models and places an emphasis on studies where PEs have been formulated with poorly permeable molecules in solid dosage forms and lipoidal dispersions.

TL;DR: The conclusion is that most of the technologies in clinical trials are incremental rather than paradigm-shifting and that even the more clinically advanced oral peptide drugs examples of oral bioavailability appear to yield Oral bioavailability values of only 1-2% and are, therefore, only currently suitable for a limited range of peptides.